Farmakoloji.2


  • Plasma Protein Binding Overview:

    • Drugs in the bloodstream exist in equilibrium between bound and unbound (free) fractions.

    • Only the unbound (free) drug fraction can cross capillary membranes, bind to target tissue receptors, undergo biotransformation, and be eliminated.

    • Plasma proteins acting as major drug carriers include albumin (primarily binds acidic and neutral drugs), α1\alpha_1-acid glycoprotein (primarily binds basic drugs), and lipoproteins.

  • Drugs with High Albumin Binding:

    • Amiodarone (99.9%99.9\% bound)

    • Dicumarol / Warfarin (99.6%99.6\% bound)

    • Diazepam

    • Phenylbutazone

    • Probenecid

    • Chlorpromazine

    • Furosemide

    • Nifedipine

    • Chlorpropamide / Tolbutamide

    • Fluoxetine

    • Indomethacin

    • Tricyclic antidepressants

    • Amphotericin B

    • Propranolol

    • Functional impact: High binding (↑\uparrow protein binding) leads to low free (active) drug levels (↓\downarrow free fraction) under normal conditions.

  • Drugs with Low Albumin Binding:

    • Lithium (0%0\% bound)

    • Alcohol

    • Acetaminophen

    • Nicotine

    • Lisinopril

    • Aminoglycosides

    • Ouabain

    • Metronidazole

    • Acyclovir

    • Gabapentin

    • Functional impact: Low binding (↓\downarrow protein binding) leads to high free drug levels (↑\uparrow free fraction) relative to total concentration.

  • Clinical Significance of Hypoalbuminemia:

    • Etiologies of Hypoalbuminemia:

      • Liver failure (decreased synthesis)

      • Renal albumin loss / Nephrotic syndrome (increased excretion)

      • Heart failure

      • Pregnancy

      • Advanced age (elderly)

    • Pathophysiology & Risk:

      • In hypoalbuminemic states, the available binding sites on albumin drop significantly.

      • For drugs that are highly albumin-bound and possess a narrow therapeutic window, loss of albumin causes a substantial spike in the unbound (free) drug concentration.

      • This sudden elevation in free active drug concentration markedly increases the risk of drug toxicity.

  • Therapeutic Window and Narrow Therapeutic Index Drugs:

    • Definition: Therapeutic window (Therapeutic range) is the range of drug concentration between the Minimal Effective Concentration (MEC / MEK) and the Minimal Toxic Concentration (MTC / MTK).

      • Therapeutic Window=MTC (MTK)−MEC (MEK)\text{Therapeutic Window} = \text{MTC (MTK)} - \text{MEC (MEK)}

      • Duration of action corresponds to the time duration where plasma drug concentration stays above the MEC.

    • Drugs with a Narrow Therapeutic Window:

      • Digoxin

      • Warfarin

      • Lithium

      • Theophylline

      • Aminoglycosides

      • Most antiepileptics

      • Most antiarrhythmics

      • General anesthetics

      • Cyclosporine

Tissue Sequestration and Organ Accumulation

  • Mechanisms and Properties of Sequestration:

    • Definition: Sequestration occurs when an ingested drug displays high affinity for specific cell types or tissues, accumulating localized concentrations far exceeding blood plasma levels.

    • Ion Trapping: Serves as a key physicochemical mechanism driving intracellular sequestration due to pH gradients across cell membranes.

    • Drug Reservoir Function: Tissue binding converts tissues into drug reservoirs (depots).

    • Delayed Onset: At the beginning of administration, a large portion of the administered dose diverts directly into tissue stores, delaying the therapeutic onset of action (e.g., Amiodarone).

    • Ineffectiveness of Dialysis: In cases of overdose or acute poisoning, hemodialysis is completely ineffective because the vast majority of the drug is sequestered in peripheral tissues rather than circulating freely in blood plasma.

  • Specific Tissue Sequestration Sites and Clinical Consequences:

    • Digoxin:

      • Sequestration Site: Skeletal muscle.

      • Clinical Outcome: Requires careful dose adjustment in cachectic patients due to reduced muscle mass.

    • Chloroquine:

      • Sequestration Site: Retina.

      • Clinical Outcome: Prolonged use causes retinal toxicity resulting in macular degeneration / maculopathy.

    • Iodine-131 (Radioactive Iodine):

      • Sequestration Site: Thyroid gland.

      • Clinical Outcome: Selective accumulation utilized in thyroid cancer radiation therapy.

    • Griseofulvin / Terbinafine:

      • Sequestration Site: Keratinized tissues (skin, hair, nails).

      • Clinical Outcome: Targeted therapy for dermatophyte fungal infections.

    • Tetracyclines:

      • Sequestration Site: Bone and teeth (binds specifically to calcium ions Ca2+Ca^{2+}).

      • Clinical Outcome: Tooth discoloration in developing teeth; teratogenicity and bone growth inhibition during pregnancy.

    • Bisphosphonates:

      • Sequestration Site: Bone.

      • Clinical Outcome: Deposition in bone matrix utilized for osteoporosis treatment.

    • Lead / Radium / Foscarnet:

      • Sequestration Site: Bone.

      • Clinical Outcome: Long-term skeletal toxicity and radiation retention.

    • Arsenic:

      • Sequestration Site: Keratinized tissues (skin, nails).

      • Clinical Outcome: Chronic toxicity produces hyperkeratosis (palmar and plantar hyperkeratosis).

    • Azithromycin:

      • Sequestration Site: Phagocytic cells (macrophages, neutrophils).

      • Clinical Outcome: Extremely long elimination half-life due to cellular entrapment.

    • Tricyclic Antidepressants:

      • Sequestration Site: Lungs.

      • Clinical Outcome: High pulmonary tissue accumulation.

    • Thiopental:

      • Sequestration Site: Adipose tissue.

      • Clinical Outcome: Deep tissue accumulation prolonging sedation.

    • Aminoglycosides:

      • Sequestration Site: Inner ear endolymph and auditory hair cells.

      • Clinical Outcome: Ototoxicity leading to irreversible hearing loss.

Apparent Volume of Distribution (VdV_d)

  • Definition and Theoretical Basis:

    • Definition: Apparent Volume of Distribution (VdV_d) is the hypothetical volume of body fluid into which a drug would need to be uniformly distributed to achieve a concentration equal to its measured plasma concentration.

    • Fundamental Formula:

      • Vd (L/kg)=Total Drug Amount in Body (g/kg)Plasma Drug Concentration (g/L)V_d\,(L/kg) = \frac{\text{Total Drug Amount in Body}\,(g/kg)}{\text{Plasma Drug Concentration}\,(g/L)}

      • Vd=Drug DosePlasma Concentration (C)V_d = \frac{\text{Drug Dose}}{\text{Plasma Concentration}\,(C)}

  • Theoretical Assumptions Underlying VdV_d Calculations:

    • To reflect a real physical anatomical volume, three strict conditions must be met:

      1. The drug must distribute homogeneously throughout the entire body.

      2. The drug must not bind to any tissue or plasma protein.

      3. No elimination or metabolism of the drug must occur.

    • Because these conditions almost never hold true in real human physiology, calculated VdV_d values are mathematical/apparent constructs rather than real anatomical volumes.

    • Extensive Tissue Sequestration (e.g., Digoxin): Digoxin binds heavily to skeletal muscle tissue. Consequently, plasma concentration (CC) is extremely low relative to total body load, resulting in an artificially huge calculated VdV_d (Vd≈6−7 L/kgV_d \approx 6 - 7\,L/kg, which equals 420−490 L420 - 490\,L in a 70 kg70\,kg adult, far exceeding total body water).

    • High Plasma Protein Binding (e.g., Warfarin): Highly bound drugs remain trapped in the vascular compartment. High plasma concentration (CC) yields a calculated VdV_d smaller than real anatomical fluid compartments.

  • Body Compartment Volumes and Representative Drugs:

    • For a standard 70 kg70\,kg human, total non-sequestered body fluid volume is approximately 42 L42\,L (0.6 L/kg0.6\,L/kg).

    • Total Body Water:

      • Volume: 0.6 L/kg0.6\,L/kg (42 L42\,L in 70 kg70\,kg individual)

      • Drug characteristics: Small, water-soluble molecules

      • Example: Ethanol

    • Extracellular Fluid (ECF):

      • Volume: 0.2 L/kg0.2\,L/kg (14 L14\,L in 70 kg70\,kg individual)

      • Drug characteristics: Large, water-soluble molecules

      • Example: Gentamicin

    • Vascular Compartment (Plasma):

      • Volume: 0.04 L/kg0.04\,L/kg (2.8 L2.8\,L in 70 kg70\,kg individual)

      • Drug characteristics: Large, protein-bound molecules

      • Example: Antibodies (Monoclonal antibodies)

    • Adipose Tissue:

      • Volume: 0.2−0.35 L/kg0.2 - 0.35\,L/kg

      • Drug characteristics: Highly lipophilic molecules

      • Example: Diazepam

    • Bone:

      • Volume: 0.07 L/kg0.07\,L/kg

      • Drug characteristics: Specific inorganic ions

      • Example: Fluoride (F−F^-)


Volume of Distribution Models

Pharmacokinetic Calculations and Dosing Principles

  • Clinical Applications of Volume of Distribution:

    • Calculates the required initial loading dose to immediately achieve a target therapeutic plasma concentration.

    • Determines total drug amount present in the body at any measured time point.

    • Estimates the elimination rate constant (KeK_e) when combined with total body clearance.

  • Essential Pharmacokinetic Formulas:

    • Elimination Rate Constant (KeK_e):

      • Ke=ClearanceVdK_e = \frac{\text{Clearance}}{V_d}

    • Elimination Half-Life (t1/2t_{1/2}):

      • t1/2=0.693×VdClearancet_{1/2} = 0.693 \times \frac{V_d}{\text{Clearance}}

      • Half-life is directly proportional to VdV_d and inversely proportional to Clearance.

    • Loading Dose:

      • Loading Dose=Vd (L/kg)×Target Plasma Concentration (mg/L)F (Bioavailability)\text{Loading Dose} = \frac{V_d\,(L/kg) \times \text{Target Plasma Concentration}\,(mg/L)}{F\,(\text{Bioavailability})}

      • An increase in VdV_d requires a proportional increase in loading dose to achieve rapid therapeutic levels.

    • Maintenance Dose:

      • Maintenance Dose=Target Plasma Concentration×ClearanceF (Bioavailability)\text{Maintenance Dose} = \frac{\text{Target Plasma Concentration} \times \text{Clearance}}{F\,(\text{Bioavailability})}

      • Maintenance dose maintains steady-state levels and depends strictly on Clearance, NOT on VdV_d.

Redistribution

  • Mechanism and Characteristics:

    • Redistribution occurs specifically with highly lipophilic drugs administered intravenously or via inhalation (e.g., general anesthetics, benzodiazepines, barbiturates such as thiopental).

    • Initial Phase (0–10 min): Highly lipophilic drug rapidly enters highly vascularized, well-perfused organs with low tissue mass, primarily the Central Nervous System (CNS / Brain). Rapid entry produces immediate pharmacological action (anesthesia/sedation).

    • Second Phase (10–60 min): As blood levels drop, drug rapidly redistributes out of the CNS into viscera and skeletal muscle tissue.

    • Third Phase (>60 min): Drug slowly transfers from muscle into adipose tissue, where it accumulates due to lipid solubility.

    • Redistribution Pathway:

      • IV Dose→CNS (Brain)→Skeletal Muscle→Adipose Tissue\text{IV Dose} \rightarrow \text{CNS (Brain)} \rightarrow \text{Skeletal Muscle} \rightarrow \text{Adipose Tissue}


Redistribution Kinetics Curve
  • Distinction from Elimination:

    • Redistribution is NOT a form of drug elimination or metabolism. The total drug molecule count remains inside the human body.

    • Redistribution is a mechanism of action termination because it removes the drug from its primary site of action (CNS receptor sites).

  • Clinical Implications:

    • Rapid IV infusion or inhalation is required during induction so that sufficient drug reaches the CNS before redistribution lowers concentration below active levels.

    • Repeated dosing leads to saturation of skeletal muscle and adipose tissue depots, preventing rapid removal from the CNS and causing prolonged recovery/awakening times (especially in obese patients).

Factors Influencing Drug Distribution and Interactions

  • Physiological Factors Affecting Distribution:

    1. Organ Size: Determines concentration gradient between blood and tissue. Skeletal muscle mass provides a vast physical reservoir.

    2. Blood Flow (Perfusion): Well-perfused organs (brain, heart, liver, kidneys) receive rapid initial drug influx. Poorly perfused tissues (fat, skin, bone) accumulate drugs slowly.

    3. Age and Sex:

      • Females generally have higher relative adipose mass and lower muscle mass than males.

      • Elderly individuals exhibit decreased skeletal muscle mass and increased body fat percentage (↑\uparrow distribution volume for lipophilic drugs).

      • Neonate infants possess higher total water percentage (↑\uparrow distribution volume for hydrophilic drugs).

    4. Blood-Brain Barrier (BBB) Permeability:

      • Lipophilic non-ionized drugs cross BBB easily.

      • Glucocorticoids reduce capillary permeability, tightening BBB.

      • BBB integrity is compromised (increasing drug penetration) during meningeal inflammation (meningitis, encephalitis) and following CNS radiation therapy.

  • Drug Interactions at the Distribution Level:

    • Albumin Binding Site Competition: Two drugs competing for the same albumin binding site result in displacement of the drug with lower affinity by the higher affinity drug, leading to elevated free plasma concentration of the displaced agent.

    • Bilirubin Displacement: Sulfonamides and derivative compounds (including loop diuretics) displace bound bilirubin from albumin, increasing free bilirubin levels and escalating neonatal jaundice/kernicterus risk.

    • Free Fatty Acid Interactions: Co-administration of drugs that reduce plasma free fatty acid levels alongside benzodiazepines reduces the free fraction of benzodiazepines by approximately 22-fold.

    • Diuretics: Decrease body fluid volume and volume of distribution, modifying co-administered drug concentrations.

    • Oral Contraceptives (OCPs): Induce fluid and sodium retention, expanding the distribution volume of antiepileptics like phenytoin. In epileptic women treated with phenytoin, starting OCPs can lower phenytoin plasma levels, triggering breakthrough seizures.

    • NSAIDs and Oral Anticoagulants (OAK): NSAIDs displace oral anticoagulants (warfarin, dicumarol) from plasma proteins, increasing free anticoagulant concentration and heightening bleeding risk and toxicity (↑\uparrow effect, ↑\uparrow toxicity).

Overview of Drug Biotransformation (Metabolism)

  • General Features:

    • Primary Organ: Liver is the primary metabolic organ, although biotransformation occurs to varying degrees in kidneys, lungs, intestines, and skin.

    • Primary Purpose: Convert lipophilic drugs into hydrophilic (polar, water-soluble) metabolites to enable efficient renal and biliary excretion.

    • Metabolite Classifications:

      • Inactive metabolites (most common outcome).

      • Active metabolites (pharmacologically active compounds).

      • Toxic or carcinogenic metabolites.

    • Prodrugs: Pharmacologically inactive parent compounds converted into active metabolites via hepatic or tissue biotransformation.

    • ACE Inhibitor Exception Rule: All ACE inhibitors are prodrugs EXCEPT Lisinopril and Captopril, which are administered directly in active form.

Comprehensive Prodrug, Active, and Toxic Metabolite Classifications

  • Prodrugs and Their Active/Toxic Metabolites:

    • Chlorazepate: Converted to Nordazepam (Anxiolytic).

    • Minoxidil: Converted to Minoxidil N-O-sulfate (Vasodilator / antihypertensive).

    • Azathioprine: Converted to Mercaptopurine (Immunosuppressive / cytostatic).

    • Cortisone: Converted to Hydrocortisone (Glucocorticoid).

    • Prednisone: Converted to Prednisolone (Glucocorticoid).

    • Enalapril: Converted to Enalaprilat (ACE inhibitor).

    • Zidovudine: Converted to Zidovudine triphosphate (Antiviral / HIV treatment).

    • Cyclophosphamide: Converted to 4-Hydroxycyclophosphamide (and aldophosphamide) (Active antineoplastic); also breaks down into Acrolein and Phosphoramide mustard (Toxic metabolites causing hemorrhagic cystitis).

  • Active Parent Drugs with Active Metabolites:

    • Imipramine: Metabolized to Desipramine (Tricyclic antidepressant).

    • Aspirin: Metabolized to Salicylic acid (Analgesic, antipyretic, anti-inflammatory).

    • Digitoxin: Metabolized to Digoxin (Cardiac glycoside).

    • Diazepam: Metabolized to Nordazepam, which further metabolizes to Oxazepam (Anxiolytics / sedatives).

    • Morphine: Metabolized to Morphine-6-glucuronide (Potent active analgesic formed via Phase II conjugation).

  • Drugs Forming Specific Toxic Metabolites:

    • Cyclophosphamide: Yields Acrolein and Phosphoramide mustard →\rightarrow causes bladder toxicity and hemorrhagic cystitis.

    • Halothane: Yields Trifluoroacetic acid →\rightarrow causes hepatotoxicity (halothane hepatitis).

    • Methoxyflurane: Yields Fluoride ions (F−F^-) →\rightarrow causes nephrotoxicity.

    • Acetaminophen (Paracetamol): Yields N-acetyl-p-benzoquinone imine (NAPQI) →\rightarrow causes severe hepatotoxicity and acute liver failure.

  • Drugs Excreted Unchanged (Minimal/No Metabolism):

    • Furosemide / Amiloride

    • Aminoglycosides

    • Digoxin

    • Penicillins

    • Sodium cromoglycate

    • Lithium

    • Gabapentin / Pregabalin

    • Nitrous oxide / Xenon

    • Clinical Significance: Dosage and clearance of these drugs are unaffected by hepatic failure; however, renal dysfunction severely impairs their elimination.

Classification of Phase I and Phase II Reactions

  • Phase I Reactions (Functionalization):

    • Oxidations (Cytochrome P450 Dependent):

      • Aromatic hydroxylation

      • Aliphatic hydroxylation

      • Epoxidation / N-Oxidation

      • N-Dealkylation / O-Dealkylation / S-Dealkylation

      • Deamination / Desulfuration / Dechlorination

    • Oxidations (Cytochrome P450 Independent):

      • Flavin-containing monooxygenase (FMO / Ziegler enzyme)

      • Amine oxidases (MAO, DAO)

      • Dehydrogenation (Alcohol/aldehyde dehydrogenase)

    • Reductions:

      • Azo reduction (R-NO2→R-NH2R\text{-}NO_2 \rightarrow R\text{-}NH_2)

      • Nitro reduction

      • Carbonyl reduction

    • Cleavage / Hydrolysis:

      • Carboxylesterase

      • Epoxide hydrolase

      • Esterases

    • Other Pathways:

      • Dihydropyrimidine dehydrogenase

    • Physicochemical Effects: Introduces or unmasks polar functional groups (−OH-OH, −NH2-NH_2, −SH-SH); slightly increases ionization and hydrophilicity.

  • Phase II Reactions (Conjugation):

    • Glucuronidation

    • Sulfation (Sulfate conjugation)

    • Acetylation

    • Methylation

    • Glutathione conjugation

    • Water conjugation

    • Glycine conjugation

    • Glutamine conjugation

    • Physicochemical Effects: Attaches endogenous polar moieties to drug molecules, dramatically increasing water solubility and abolishing biological activity.

  • Comparative Physicochemical Properties:

    • Lipophilic Drugs: Non-ionized / non-polar, fat-soluble, readily cross cell membranes and BBB, insoluble in plasma, highly bound to plasma proteins, heavily metabolized in liver, excreted via bile, high oral bioavailability.

    • Hydrophilic Drugs: Ionized / polar, water-soluble, cannot cross lipid membranes or BBB, highly soluble in plasma, low plasma protein binding, un-metabolized in liver, excreted directly via kidneys (urine), low oral bioavailability.

Phase I Enzymes: Cytochrome P450 and Non-Microsomal Systems

  • Microsomal Enzyme System:

    • Subcellular Location: Embedded in the smooth endoplasmic reticulum (SER) membrane of hepatocytes and extrahepatic tissues.

    • Key Enzyme Groups: Cytochrome P450 (CYP) monooxygenases and Flavin-containing monooxygenases (FMO / Ziegler enzyme).

    • Biochemical Requirements: Active site contains a heme iron ion (FeFe); requires cofactors NADPH and molecular oxygen (O2O_2).

    • Inducibility: Microsomal enzymes are highly susceptible to enzyme induction (leading to hepatic cellular hyperplasia) and enzyme inhibition.

    • Flavin-containing Monooxygenase (FMO / Ziegler Enzyme):

      • Responsible for less drug metabolism than CYP systems.

      • Immune to induction or inhibition.

      • Exclusively forms benign, non-toxic metabolites.

      • FMO-3 Deficiency: Results in failure to metabolize trimethylamine, causing accumulation of trimethylamine N-oxide in human sweat and breath, clinically manifested as fish odor syndrome.

  • Non-Microsomal Enzymes:

    • Monoamine Oxidase (MAO): Located in outer mitochondrial membranes (CNS, gut wall).

    • Xanthine Oxidase: Located in cytoplasm (liver, kidney).

    • Tyrosine Hydroxylase: Located in adrenergic neurons.

  • Cytochrome P450 Isoenzyme Distribution and Properties:

    • CYP3A4 / CYP3A5: Responsible for metabolizing ∼50%\sim 50\% of all clinically used drugs. Most abundant CYP isoenzyme in human liver.

    • CYP2D6: Responsible for metabolizing ∼25%\sim 25\% of drugs. Displays highest degree of genetic polymorphism in Phase I. CYP2D6 is NOT inducible by external agents.

    • CYP2B6: Responsible for metabolizing ∼1%\sim 1\% of clinical drugs.

    • CYP19 (Aromatase): Does NOT metabolize exogenous drugs. Performs endogenous conversion of Testosterone into Estradiol (Testosteron→O¨stradiol\text{Testosteron} \rightarrow \text{Östradiol}).


CYP Isoenzyme Distribution

Genetic Polymorphisms in Drug Metabolism

  • Phenotypic Categories:

    • Poor Metabolizers: Reduced enzyme activity. Leads to elevated plasma levels of active drugs (↑\uparrow toxicity risk) and diminished conversion of prodrugs (↓\downarrow therapeutic efficacy).

    • Extensive / Normal Metabolizers: Standard baseline enzymatic conversion rate.

    • Ultrarapid Metabolizers: Gene duplication/overexpression. Leads to rapid therapeutic failure of standard active drugs (↓\downarrow plasma levels) and exaggerated rapid activation of prodrugs (↑\uparrow toxicity).

  • Detailed CYP Enzyme Polymorphisms and Clinical Manifestations:

    • CYP1A2: Defect: N-Demethylation.

      • Fast Phenotype: Decreased CNS stimulation from caffeine.

      • Slow Phenotype: Exaggerated CNS stimulation and prolonged caffeine half-life.

    • CYP2A6: Defect: Oxidation.

      • Slow Phenotype: Nicotine toxicity with reduced smoking urge; increased bleeding from coumarin.

      • Fast Phenotype: Rapid nicotine breakdown with increased smoking craving; increased clearance of coumarin (thrombosis risk).

    • CYP2B6: Defect: Oxidation.

      • Slow Phenotype: Decreased clearance of Cyclophosphamide, Ifosfamide, Efavirenz, and Nevirapine (↑\uparrow adverse effects).

    • CYP2C8: Defect: Hydroxylation / Deethylation.

      • Slow Phenotype: Reduced clearance of Repaglinide, Rosiglitazone, Pioglitazone, Paclitaxel, Amodiaquine, Chloroquine, and Amiodarone (↑\uparrow adverse effects).

    • CYP2C9: Defect: Hydroxylation.

      • Slow Phenotype:

        • NSAIDs (Celecoxib, Diclofenac, Flurbiprofen, Ibuprofen): Decreased clearance.

        • Warfarin / Acenocoumarol: Markedly increased bleeding risk; requires dose reduction.

        • Tolbutamide: Cardiotoxicity.

        • Phenytoin: Toxicity manifested as nystagmus, diplopia, and ataxia.

    • CYP2C19: Defect: N-Demethylation, O-Demethylation, Hydroxylation, Oxidative Cyclization.

      • Slow Phenotype: Reduced clearance of Amitriptyline, Clomipramine, Moclobemide, Citalopram, Omeprazole, Mephenytoin. Elevated therapeutic efficacy for Omeprazole; increased GI side effects for SSRIs.

      • Fast Phenotype: Increased gene transcription resulting in reduced therapeutic efficacy for Escitalopram and Omeprazole; increased activation and efficacy for Tamoxifen, Chlorproguanil, and Clopidogrel.

    • CYP2D6: Defect: Oxidation, O-Demethylation, N-Demethylation, Hydroxylation.

      • Slow Phenotype:

        • Bufuralol: Enhanced beta-blockade, nausea.

        • Codeine: Failure to convert codeine to morphine →\rightarrow loss of analgesic efficacy.

        • Debrisoquine: Severe orthostatic hypotension.

        • Nortriptyline / Dextromethorphan: Decreased clearance, severe side effects.

        • Tramadol: Increased seizure/epilepsy risk due to lack of conversion to active opioid metabolite.

        • Tamoxifen: Impaired conversion to Endoxifen →\rightarrow loss of antineoplastic efficacy.

        • Metoprolol: Markedly elevated plasma levels →\rightarrow severe bradycardia and hypotension.

      • Ultrarapid Phenotype:

        • Codeine: Hyper-rapid conversion to morphine →\rightarrow fatal respiratory depression risk.

        • Nortriptyline / Tramadol: Ultra-high clearance →\rightarrow therapeutic failure.

    • CYP3A4 / CYP3A5:

      • CYP3A4 Slow Phenotype: Impaired clearance of all CYP3A4 substrates; requires strict dose reductions to prevent severe drug interactions.

      • CYP3A5 Slow Phenotype: Altered pharmacokinetics of Saquinavir, Midazolam, and Tacrolimus; associated with high organ transplant rejection rates in individuals of African ancestry.

  • Non-CYP Enzyme Polymorphisms:

    • Aldehyde Dehydrogenase (ALDH): Slow defect →\rightarrow Ethanol administration causes acetaldehyde accumulation leading to facial flushing, hypotension, tachycardia, nausea, and vomiting (disulfiram reaction).

    • Butyrylcholinesterase (BCHE / Pseudocholinesterase): Defect in ester hydrolysis. Slow phenotype →\rightarrow Prolonged respiratory muscle paralysis/apnea with Succinylcholine and Mivacurium; severe hypertension and ventricular arrhythmias with Cocaine.

    • Glutathione S-Transferase (GST): Gene deletion causes defective GSH conjugation →\rightarrow impaired clearance of Acetaminophen and Busulfan.

    • N-Acetyltransferase 2 (NAT2): Defect in N-acetylation. Slow acetylator phenotype →\rightarrow Drug-induced systemic lupus erythematosus-like syndrome from Hydralazine; peripheral neuropathy from Isoniazid.

    • Thiopurine S-Methyltransferase (TPMT): Defect in S-methylation. Slow phenotype →\rightarrow Severe, life-threatening bone marrow suppression / myelotoxicity from 6-Mercaptopurine and 6-Thioguanine.

    • UDP-Glucuronosyltransferase 1A1 (UGT1A1): Defect in glucuronidation. Slow phenotype →\rightarrow Hyperbilirubinemia (Gilbert / Crigler-Najjar syndromes); severe toxicity and reduced clearance of Irinotecan (requires dose adjustment); increased jaundice risk with Atazanavir.

  • HLA Gene Polymorphisms and Severe Adverse Reactions:

    • HLA-A*31:01: Carbamazepine-induced severe cutaneous adverse reactions.

    • HLA-B*57:01: Abacavir hypersensitivity syndrome / severe skin toxicity.

    • HLA-B*58:01: Allopurinol-induced Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN).

    • HLA-DRB1-DRB5-DQB1: Amoxicillin-clavulanic acid-induced hepatotoxicity.

    • HLA-B*15:02: Carbamazepine- and Phenytoin-induced Stevens-Johnson syndrome (SJS) in Asian populations.

    • HLA-B*57:01: Flucloxacillin-induced liver injury.

    • HLA-DRB1: Ximelagatran-induced liver toxicity / ALT elevation.

    • HLA-DQB1 / HLA-DRB1: Cholestatic jaundice and hepatic injury caused by anti-tuberculosis therapy (Isoniazid, Rifampin, Ethambutol).

  • Transporter and Other Pharmacogenetic Mutations:

    • SLCO1B1 (OATP1B1): Encodes hepatic uptake transporter OATP1B1. Mutation decreases hepatic uptake of statins, methotrexate, and bilirubin →\rightarrow causes Simvastatin-induced myopathy.

    • OCT1: Mutation impairs hepatic uptake of metformin →\rightarrow increases Metformin-induced lactic acidosis risk.

    • G6PDX: Glucose-6-phosphate dehydrogenase deficiency →\rightarrow Rasburicase-induced hemolytic anemia and methemoglobinemia.

    • IL28B (Interferon Lambda-3): Polymorphism dictates antiviral response rate to Interferon-alpha + Ribavirin therapy in Hepatitis C.

    • ABCG2 (BCRP): Efflux transporter mutation alters clinical response to Allopurinol and Rosuvastatin; increases chemotherapy toxicity.

    • CACNA1S and RYR1: Ryanodine receptor / calcium channel mutations →\rightarrow triggers Malignant Hyperthermia upon exposure to volatile anesthetics (Desflurane, Enflurane, Halothane, Isoflurane, Methoxyflurane, Sevoflurane) or Succinylcholine.

    • KCNIP4: Linked to ACE inhibitor-induced cough susceptibility.

Inducers and Inhibitors of Cytochrome P450 Enzymes

  • Cytochrome P450 Enzyme Inhibitors:

    • Cimetidine

    • Chloramphenicol

    • Metronidazole

    • Isoniazid (Dual inhibitor/inducer)

    • Grapefruit juice (contains Naringin and Furanocoumarins)

    • Red wine

    • Carbon monoxide (CO)

    • Alcohol (Acute administration)

    • Amiodarone

    • Oral contraceptives

    • Ritonavir (Acute administration - extremely potent inhibitor)

    • Macrolide antibiotics (Clarithromycin, Erythromycin - specifically CYP3A4; Streptogramins)

    • Antifungals (Ketoconazole - CYP3A4, Fluconazole, Itraconazole)

    • Fluoroquinolones (Ciprofloxacin, Norfloxacin, Enoxacin)

    • SSRIs (Fluoxetine, Paroxetine, Sertraline, Fluvoxamine)

    • Calcium Channel Blockers (Nifedipine, Nicardipine, Diltiazem, Verapamil)

    • Antipsyhotics (Haloperidol, Thioridazine)

    • Other Inhibitors: Quinidine, Valproic acid, Nefazodone, Disulfiram, Dicumarol, Ticlopidine, Clopidogrel, Co-trimoxazole, Trimethoprim, Allopurinol, Antihistamines, Androgenic steroids, Propylthiouracil, Phenylbutazone, Spironolactone, Omeprazole.

  • Cytochrome P450 Enzyme Inducers:

    • Barbiturates (except secobarbital)

    • Phenytoin

    • Carbamazepine

    • Rifampin

    • Griseofulvin

    • Cigarette smoke (polycyclic aromatic hydrocarbons)

    • Alcohol (Chronic administration)

    • Glucocorticoids

    • Nafcillin

    • Rifabutin

    • Pioglitazone (Dual modifier)

    • Clofibrate

    • Tolbutamide

    • Cyclophosphamide

    • Phenylbutazone (Dual modifier)

    • Omeprazole (Dual modifier)

    • Isoniazid (Dual modifier)

    • Ritonavir (Chronic administration)

    • St. John's Wort (severe risk of Serotonin Syndrome when combined with SSRIs).

  • Critical Complex Enzyme Interactions:

    • Alcohol and Ritonavir: Acute ingestion produces potent enzyme inhibition. Conversely, chronic continuous intake induces CYP enzymes.

    • Dual Modifiers: Isoniazid, Pioglitazone, Phenylbutazone, and Omeprazole possess differential effects across the >50 CYP isoenzymes, acting as inducers for certain subtypes and inhibitors for others.

    • Omeprazole Subtype Duality: Selectively inhibits CYP2C19 (elevating plasma phenytoin and disulfiram levels to toxic ranges) while simultaneously inducing CYP1A2 (decreasing plasma imipramine and theophylline concentrations).

Specialized Biotransformation Pathways and Phase II Characteristics

  • Pharmacokinetic Auto-Induction (Pharmacokinetic Tolerance):

    • Certain drugs induce the specific CYP enzymes responsible for their own metabolic clearance (e.g., Carbamazepine, Phenytoin, chronic alcohol).

    • Continuous administration accelerates their own elimination rate over time, requiring progressive dose increases to maintain therapeutic effect (pharmacokinetic tolerance).

  • Reductive Metabolic Pathways:

    • Infrequent pathway in mammalian physiology.

    • Examples of drugs metabolized via reduction (R-NO2→R-NH2R\text{-}NO_2 \rightarrow R\text{-}NH_2): Prednisone, Warfarin, Chloramphenicol.

  • Hydrolytic Pathways and Specific Enzymes:

    • Digitalis Glycosides: Monosaccharide sugar chains are cleaved off by tissue β\beta-glucosidase to yield active aglycone.

    • Epoxide Hydrolase: Responsible for clearing carbamazepine-10,11-epoxide (the active/toxic metabolite of carbamazepine). Valproic acid inhibits epoxide hydrolase, precipitating carbamazepine toxicity.

    • Carboxylesterase: Cleaves irinotecan into its active antineoplastic form.

    • Acetylcholinesterase: Hydrolyzes endogenous Acetylcholine as well as exogenous drugs: Atropine, Scopolamine, Procaine, and Remifentanil.

  • Detailed Phase II Reaction Mechanisms and Subcellular Localization:

    1. Glucuronidation:

      • Endogenous Donor: UDP-glucuronic acid

      • Enzyme: UDP-glucuronosyltransferase (UGT)

      • Substrates: Bilirubin, Steroids, Morphine, Acetaminophen, Diazepam

      • Subcellular Localization: Microsomal enzymes (Smooth Endoplasmic Reticulum)

    2. Acetylation:

      • Endogenous Donor: Acetyl-CoA

      • Enzyme: N-Acetyltransferase (NAT)

      • Substrates: Hydralazine, Isoniazid, Procainamide, Sulfonamides

      • Subcellular Localization: Cytoplasm

    3. Glutathione Conjugation:

      • Endogenous Donor: Glutathione (GSH)

      • Enzyme: GSH-S-Transferase (GST)

      • Substrates: Ethacrynic acid, Bromobenzene

      • Subcellular Localization: Cytoplasm + Microsomal

    4. Glycine Conjugation:

      • Endogenous Donor: Glycine

      • Enzyme: Acyl-CoA glycine transferase

      • Substrates: Nicotinic acid, Salicylic acid

      • Subcellular Localization: Mitochondria

    5. Sulfation / Sulfate Conjugation:

      • Endogenous Donor: 3'-Phosphoadenosine-5'-phosphosulfate (PAPS)

      • Enzyme: Sulfotransferase (SULT)

      • Substrates: Coumadin (Warfarin), Methyldopa, Estrogen, Acetaminophen

      • Subcellular Localization: Cytoplasm

    6. Methylation:

      • Endogenous Donor: S-Adenosylmethionine (SAM)

      • Enzyme: Transmethylase / Methyltransferase

      • Substrates: Dopamine, Epinephrine, Histamine, Thiouracil

      • Subcellular Localization: Cytoplasm

    7. Water Conjugation:

      • Endogenous Donor: Water (H2OH_2O)

      • Enzyme: Epoxide hydrolase

      • Substrates: Leukotriene A4 (LTA4LTA_4)

      • Subcellular Localization: Microsomal (epoxide hydrolase) + Cytosol